Cardiff – CFI is pleased to announce that it acted as exclusive financial advisor to Creo Medical Group in its acquisition of securing a multi-million pound commercial mortgage from Barclays Bank.
Creo Medical was founded in 2003 by Professor Chris Hancock, initially to target the treatment of cancers through use of high frequency microwave energy and dynamic matching techniques. Creo now provides an expanding range of innovative medical devices designed for endoscopy surgeries, with flagship technologies including Kamaptive™, Speedboat™, MicroBlate™, SlypSeal™ and SpyderBlade™. The Company was listed on the London Stock Exchange in 2016 and has since witnessed impressive global growth both organically and via landmark acquisitions including Albyn Medical and Boucart Medical. Creo has raised in excess of £150m via share placings since its IPO.
CFI UK has acted as lead financial advisor to Creo Medical Group Plc (AIM: CREO) in securing a multi-million pound funding package from Barclays.
The funding will be used to expand the Company’s current operating facilities, following the multi-million pound acquisition of Creo House and its adjacent site in July 2021. The additional space will accommodate a rising number of employees, increased commercial activity and manufacturing capacity, underpinned by the two acquisitions undertaken in 2020 and general corporate purposes. Development plans include the construction of a multi-storey ‘link building’ to bridge its existing sites and the addition of a mezzanine floor to the car park.
This transaction closed on 24 June 2022.
has acquired a majority share in
has sold its ceramics business to
its radiation measurement device business and the industrial X-ray CT device business